(1)永久形變 因?yàn)镺形密封圈通常使用的材料具有粘彈性，其回彈堵塞能力和初始值使用的時(shí)間較長(zhǎng)，并造成永久變形，逐步消失，最后造成滲漏現(xiàn)象。

We present a case of a healthy 32-year-old man who developed bilateral corneal ulceration 3wk after commencing dupilumab for atopic dermatitis. Dupilumab is a recently introduced systemic monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis, showing efficacy in clinical trials

. Several publications have reported ocular surface complications associated with dupilumab,including conjunctivitis, blepharitis, and superficial keratitis,though we report a novel case of dupilumab-associated bilateral corneal ulceration. This study is in accordance with the tenets of the Declaration of Helsinki and written informed consent has been obtained from the patient.

A 32-year-old man presented to the Royal Victorian Eye and Ear Hospital (RVEEH), referred from a private ophthalmologist,with severe, worsening bilateral ulcerative keratitis for over a week.

The patient had initially noted right eye irritation and redness,with bilateral (OU) photophobia and epiphora, prompting ophthalmology review. He was treated with one week of ofloxacin and gentamycin eye drops OU 2 hourly while awake and chloramphenicol ointment at night. On re-review, his vision had deteriorated from 6/9 in each eye, to right visual acuity(RVA) of counting fingers at 1m (CF@1 m) and left visual acuity (LVA) of 6/18, and he was referred to the RVEEH.Previous ocular history included a skin cancer removal from a left lower lid tear duct. Medical history was notable for atopic dermatitis, ulcerative bladder post childhood trauma and epilepsy. Systemic medication included sodium valproate,mycophenolate, oxybutynin and dupilumab subcutaneous injections. Dupilumab injections, including an initial 600 mg loading dose followed by a maintenance dose of 300 mg every second week, had been commenced 4wk prior. Onset of ocular symptoms were first noted 3wk post first dupilumab dose.All other systemic medications had remained unchanged for multiple years.

On final follow up, 2wk post discharge, patient had received no further dupilumab treatment. His BCVA was 6/9 OD and 6/7.5 OS. His intraocular pressure (IOP) was 12 mm Hg OD and 17 mm Hg OS. His right eye had no further epithelial defect or stromal opacities and the left eye had some very mild peripheral punctate opacities. The blepharitis was noted to be mild OU, and the bilateral ectropions had largely resolved.

Right eye corneal scrape and swab was taken, including 2 glass slides for gram and blankophor stain, blood agar,chocolate agar, a fungal slope, broth, an acanthamoeba slope,a viral polymerase chain reaction (PCR) and a gonococcal and chlamydia PCR.

The patient was admitted and commenced on ofloxacin 0.3%eye drops OD 1 drop hourly day and night, sodium hyaluronate 0.2% eyedrops OS 2

hourly during the day, oral valaciclovir 500 mg three times a day and oral doxycycline 50 mg twice a day.Patient remained stable with only minor improvements despite 72h of intensive treatment. Bacterial and fungal microbiology and viral PCR [including herpes simplex virus (HSV) type 1& 2, and varicella zoster, cytomegalovirus and adenovirus]were negative for all organism growth and, on day 3 of admission, fluorometholone 0.1% eye drops four times a day(QID) OU was commenced and chloramphenicol ointment twice daily OU to the lids. On day 4, patient was noted to be improving clinically with the epithelial defect measuring less than 0.5 mm and dense infiltrate measuring 1.5×1.5 mm

. He had almost complete resolution of his ocular symptoms and was discharged home for outpatient follow up.

On presentation to the RVEEH, his best corrected visual acuity(BCVA) was 6/36 right eye (OD) and 6/6 left eye (OS). On slit lamp examination, he had peripheral ulcerative keratitis in the right eye worse than the left. The right eye had 2 corneal defects: a 6×2.5 mm

paralimbal, deep-stromal infiltrate from 3 to 6 o’clock with an overlying epithelial defect, and a 3×1 mm

deep-stromal infiltrate at 11 o’clock on the limbal edge with overlying epithelial defect (Figures 1 and 2). He had severe blepharitis of the lid margins bilaterally, with a lateral ectropion OD and medial ectropion OS. Anterior segment findings showed an injected limbal flush of the right eye. Flare was noted in the anterior chamber but no cells or hypopyon.

經(jīng)過(guò)多次測(cè)試運(yùn)行，統(tǒng)計(jì)出平均識(shí)別率，得到在不同像素分類情況下PNN的識(shí)別率。見(jiàn)表1。除此之外，在以上結(jié)論的前提下（10像素組擁有最佳的識(shí)別效果）與PNN神經(jīng)網(wǎng)絡(luò)相似的BP神經(jīng)網(wǎng)絡(luò)以及LVQ神經(jīng)網(wǎng)絡(luò)也使用相同的特征矩陣進(jìn)行了識(shí)別工作，與其進(jìn)行了橫向?qū)Ρ取榱藢?duì)比的公平，BP神經(jīng)網(wǎng)絡(luò)和LVQ神經(jīng)網(wǎng)絡(luò)將采用相同的10像素組特征矩陣進(jìn)行訓(xùn)練和分類。

In his left eye, the cornea had no epithelial defect, though 2 sub-epithelial infiltrates (＜1 mm diameter) were noted superiorly. Anterior chamber showed no signs of intraocular inflammation.

(3)在1∶5萬(wàn)的高磁異常中，磁異常強(qiáng)度一般在400～2000nT之間，在鐵礦體的分布范圍內(nèi)，磁異常強(qiáng)度可達(dá)到3000～6000nT，可直接反映含礦帶或礦體的特征。磁異常ΔT上延100m垂向二階導(dǎo)數(shù)>0值范圍可作為找礦重點(diǎn)靶區(qū)。南北側(cè)伴生有明顯的負(fù)磁異常，負(fù)磁場(chǎng)強(qiáng)度達(dá)-225nT。高精度磁測(cè)對(duì)尋找隱伏礦體，指導(dǎo)探礦工程的布設(shè)，具有良好的地質(zhì)效果。

Associated with a genetic predisposition, atopic dermatitis is a chronic inflammatory skin disease, affecting 10% of adults and 20% of children worldwide. It is a complex immune and autonomic dysfunction disorder with a pathogenesis determined by Th2-mediated inflammation

. Characterised by severe pruritus, the mainstay of treatment has been topical corticosteroids. However, for the 20% of patients who suffer from moderate-to-severe atopic dermatitis, the requirement for prolonged topical and oral steroid use can result in severe side effects such as hypothalamo-pituitary adrenal(HPA) axis suppression and skin atrophy

. Dupilumab is a recently introduced systemic monoclonal antibody used in the treatment for moderate-to-severe atopic dermatitis. It works by binding to the alpha subunit of the interleukin (IL)-4 and IL-13 receptor, blocking the downstream signalling cascade of IL-4 and IL-13, downregulating inflammatory mediators and upregulating structural proteins, lipid metabolism proteins,and epidermal barrier proteins

. It is also reported to reduce serum levels of CCL17, a main regulator of Th2-mediated immunity

. Dupilumab has shown efficacy in the treatment of atopic dermatitis both in clinical trials and systematic review, observing a 70% reduction in Eczema Area and Severity Index (EASI) scores after 16wk of treatment

. The most commonly reported adverse side effect of dupilumab is conjunctivitis with 26.1%

. More common in patients with severe atopic dermatitis or previous episodes of allergic conjunctivitis, most cases were mild to moderate and resolved by the end of the treatment period

. In most studies the type of conjunctivitis was not described. Blepharitis was present in 9.6% and keratitis in 6.2%

. In most cases, keratitis only involved the superficial cornea, with diagnosis of superficial punctate keratopathy, inferior punctate keratitis or dry eye.More serious cases of ocular surface disease have been described, including a case of unilateral corneal ulceration, a cicatrising blepharoconjunctivitis with punctal stenosis and cicatricial ectropion and a case of conjunctival cicatrisation and symblepharon formation

.

The onset of corneal ulceration, in a previously healthy cornea,in relation to the commencement of dupilumab treatment is highly suggestive of a dupilumab-induced effect. The patient had no previous history of ocular surface disease, and the corneal ulceration completely resolved with topical steroid treatment and cessation of dupilumab.

The pathogenesis of dupilumab-associated ocular adverse effects remains unclear. With dupilumab inhibiting goblet cell and mucin production through IL-4 & IL-13 blockade this may contribute to tear film insufficiencies and subsequent corneal erosions

. Other plausible hypotheses postulate the unmasking of pre-existent subclinical atopic or allergic inflammatory processes; increased expression of pro-inflammatory molecules (

, OX40L) and a local immunodeficiency resulting in local bacterial and viral infections

. Interestingly, there was no apparent difference in ocular adverse effects between dupilumab and placebo in patients treated for other allergic disease such as asthma,nasal polyposis or eosinophilic oesophagitis

. This suggests that rather than the effect of dupilumab being the implicit cause of ocular surface disease, there may be an underlying inflammatory mechanism (or co-existing ocular condition)associated with the interaction between atopic dermatitis and dupilumab. With an association between atopic dermatitis and a higher incidence of ocular surface disease, we postulate that combined with the effect of tear film disruption and subsequent dry eye of dupilumab, may create a compounding environment that predisposes an individual to ocular surface diseases such as keratitis.It is also noted that the patients’ lower eyelid ectropions were largely resolved on final follow up. This is likely due to the clinical improvement of the patients inflamed,blepharitic eyelid margins after cessation of dupilumab and the implementation of medical treatment. Recent reports of eyelid related adverse effects, including ectropion, associated with dupilumab use warrants further ongoing research

.

要用不規(guī)則形狀、圓形、長(zhǎng)方形等形狀和線條對(duì)背景進(jìn)行構(gòu)圖，將幻燈片背景繪制成一幅美麗的圖畫(huà)。PowerPoint版本升級(jí)到今天的2016版，繪畫(huà)功能和效果設(shè)置已經(jīng)越來(lái)越接近Flash和Photoshop的相應(yīng)功能，在繪制完成后，如果不滿意還可以通過(guò)編輯頂點(diǎn)進(jìn)行適當(dāng)?shù)男薷摹?/p>

As the use of dupilumab increases in the population, we may see an increase in associated ocular surface disease,including corneal ulceration. Dermatologists prescribing dupilumab should be aware of these risks and be vigilant for ocular symptoms such as changes in vision, pain, redness and discharge. We also believe that these patients should have a prompt evaluation with an ophthalmologist to exclude any corneal infiltration.

None;

None;

None.

1 Gooderham MJ, Hong HCH, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis.

2018;78(3 Suppl 1):S28-S36.

2 Mayba JN, Gooderham MJ. Review of atopic dermatitis and topical therapies.

2017;21(3):227-236.

3 Wang FP, Tang XJ, Wei CQ, Xu LR, Mao H, Luo FM. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.

2018;90(2):190-198.

4 Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP.Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis.

2021;84(1):139-147.

5 Li G, Berkenstock M, Soiberman U. Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis.

2020;19:100848.

6 Wohlrab J, Werfel T, Wollenberg A. Pathomechanism of dupilumabassociated inflammatory eye symptoms.

2019;33(11):e435-e436.

7 Akinlade B, Guttman-Yassky E, de Bruin-Weller M,

. Conjunctivitis in dupilumab clinical trials.

2019;181(3):459-473.

8 Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management.

2018;154(12):1485-1486.

9 Lee DH, Cohen LM, Yoon MK, Tao JP. Punctal stenosis associated with dupilumab therapy for atopic dermatitis.

2021;32(7):737-740.

10 Gooderham M, McDonald J, Papp K. Diagnosis and management of conjunctivitis for the dermatologist.

2018;22(2):200-206.

11 Park S, Lee JH, Park JH, Park SH, Park SY, Jung YW, Choi SA.Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase.

2021;11(1):14293.